NCT05635630View on ClinicalTrials.gov

Predictive Value of ctDNA for NED Status in mCRC and Its Utility in Guiding Therapeutic Intervention

NARecruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

June 24, 2022

Primary Completion Date

December 24, 2023

Study Completion Date

December 24, 2025

Conditions
Metastatic Colorectal CancerNo Evidence of Disease StatusctDNA Monitoring
Interventions
OTHER

ctDNA and adjuvant therapy

Patients of ctDNA positive group receive individual adjuvant chemotherapy. The ctDNA status are evaluated every 2 months.

OTHER

ctDNA

Patients of ctDNA negative group are monitored by ctDNA every 3 months.

Trial Locations (1)

200000

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
collaborator

Guangzhou Burning Rock Dx Co., Ltd.

INDUSTRY

lead

Fudan University

OTHER